Monte Rosa Therapeutics, Inc. (GLUE)

NASDAQ: GLUE · IEX Real-Time Price · USD
9.16
-0.56 (-5.76%)
Dec 5, 2022 3:33 PM EST - Market open
-5.76%
Market Cap 470.44M
Revenue (ttm) n/a
Net Income (ttm) -101.16M
Shares Out 46.73M
EPS (ttm) 5.09
PE Ratio 1.80
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 71,097
Open 9.7
Previous Close 9.72
Day's Range 9.02 - 9.72
52-Week Range 6.05 - 22.16
Beta n/a
Analysts Buy
Price Target 23.57 (+157.3%)
Earnings Date Nov 9, 2022

About GLUE

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurod... [Read more]

Industry Biotechnology
IPO Date Jun 24, 2021
Employees 118
Stock Exchange NASDAQ
Ticker Symbol GLUE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for GLUE stock is "Buy." The 12-month stock price forecast is 23.57, which is an increase of 157.31% from the latest price.

Price Target
$23.57
(157.31% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

– Initiated Patient Dosing in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors –

3 weeks ago - GlobeNewsWire

Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-direct...

BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the compan...

1 month ago - GlobeNewsWire

Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader-based medicines, today announced the company will...

1 month ago - GlobeNewsWire

Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium

– New and Updated Preclinical Data Highlight Potential of GSPT1-directed Molecular Glue Degrader (MGD) MRT-2359 in the Treatment of MYC-driven Cancers –

1 month ago - GlobeNewsWire

Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directe...

– Phase 1/2 Clinical Trial in Patients with MYC-driven Solid Tumors Expected to Dose in Q4 2022 – – Phase 1/2 Clinical Trial in Patients with MYC-driven Solid Tumors Expected to Dose in Q4 2022 –

2 months ago - GlobeNewsWire

Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates

– Submitted Investigational New Drug (IND) Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader for the Treatment of Myc-driven Solid Tumors –

3 months ago - GlobeNewsWire

Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

– Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSPT1-directed Molecular Glue Degrader in Solid Tumors; Company on Track to File I...

6 months ago - GlobeNewsWire

Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MR...

– Data Highlight Essential Role of GSPT1 in Sustaining Myc-induced Translational Addiction in Solid Tumors –

7 months ago - GlobeNewsWire

Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

– Company on Track for Mid-year Filing of Investigational New Drug (IND) Application for Lead Candidate MRT-2359 –

8 months ago - GlobeNewsWire

Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Resea...

BOSTON and REHOVOT, Israel, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, announced a licens...

10 months ago - GlobeNewsWire

Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company is sc...

11 months ago - GlobeNewsWire

Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D.

BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced the promotion of Julli...

1 year ago - GlobeNewsWire

Monte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced members of its managem...

1 year ago - GlobeNewsWire

Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Bu...

– Initiated Investigational New Drug (IND)-Enabling Activities for MRT-2359, a Molecular Glue Degrader Selectively Targeting GSPT1 –

1 year ago - GlobeNewsWire

Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit

BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Sharon Townson, ...

1 year ago - GlobeNewsWire

Monte Rosa Therapeutics Presents Preclinical Data at AACR-NCI-EORTC Highlighting Potential of Molecular Glue Degrader...

Data Demonstrate Novel Link Between GSPT1 and Myc-induced Transcription and Protein Translation Data Demonstrate Novel Link Between GSPT1 and Myc-induced Transcription and Protein Translation

1 year ago - GlobeNewsWire

Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-N...

BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that preclinical dat...

1 year ago - GlobeNewsWire

Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes

BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that it will be adde...

1 year ago - GlobeNewsWire

Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Markus Warmuth,...

1 year ago - GlobeNewsWire

Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress

– Completed upsized $255.6 million IPO; cash runway extended into late 2024

1 year ago - GlobeNewsWire

6 Companies Are Making Their Trading Debuts. What Investors Need to Know.

The IPO tidal wave continued Thursday, with a mix of healthcare and technology startups making their trading debut.

Other symbols: CFLTDOCSBHGMIRO
1 year ago - Barrons

Monte Rosa Therapeutics Announces Pricing of Initial Public Offering

BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body's ...

1 year ago - GlobeNewsWire